Floatz logo

JAB 3312

KRAS P.G12C

Allist Pharmaceuticals, Inc.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the KRAS P.G12C cohort.

Asset / SponsorPhaseRating
Jab-21822
Allist Pharmaceuticals, Inc.
Phase 2B
Sotorasib
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2B
Adagrasib
ETOP IBCSG Partners Foundation
Phase 2CCC
Irinotecan
Devalingam Mahalingam
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
D3 Bio (Wuxi) Co., Ltd
Phase 1/2CCC

View all 13 →

Same molecule, other indications

JAB 3312 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →